FDA told more study on testosterone treatments needed; AbbVie's AndroGel a leading product in that niche
An expert panel recommended that the Food and Drug Administration tighten restrictions on the use of testosterone drugs, a move that could put a dent in sales of one of AbbVie’s billion-dollar drugs.
Bloomberg explained that North Chicago-based AbbVie (NYSE: ABBV) pulled in about $1.04 billion in sales of its testosterone therapy AndroGel last year. But the panel of FDA advisers voted 20-1 in favor of new trials to learn more about heart risks from various testosterone drugs, the report said,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Source Type: research
More News: AndroGel | Cardiology | Food and Drug Administration (FDA) | Health Management | Heart | Learning | Pharmaceuticals | Study | Universities & Medical Training